Compare DOX & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOX | RGEN |
|---|---|---|
| Founded | 1982 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.1B |
| IPO Year | 1998 | 1995 |
| Metric | DOX | RGEN |
|---|---|---|
| Price | $66.09 | $114.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $92.33 | ★ $173.09 |
| AVG Volume (30 Days) | ★ 1.4M | 819.7K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $141,236,000.00 |
| Revenue This Year | $4.46 | $14.11 |
| Revenue Next Year | $3.72 | $14.71 |
| P/E Ratio | ★ $13.65 | $132.19 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $65.74 | $102.97 |
| 52 Week High | $94.61 | $175.77 |
| Indicator | DOX | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 28.92 |
| Support Level | N/A | $113.07 |
| Resistance Level | $70.61 | $132.51 |
| Average True Range (ATR) | 1.92 | 6.42 |
| MACD | 0.17 | -0.57 |
| Stochastic Oscillator | 13.39 | 6.23 |
Amdocs Ltd is a provider of software and services to communications, entertainment, and media service providers. The Company operates in a single segment and designs, develops, markets, supports, implements, and operates open and modular cloud offerings. Its portfolio includes solutions across digital business systems and legacy business and operational support systems, supporting multiple lines of business such as wireless, broadband, cable, fiber, satellite, and digital services. The Company leverages artificial intelligence to support digital transformation, cloud adoption, and intelligent network automation. Geographically, it derives a majority of its revenue from North America and also operates in Europe and the rest of the world.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.